Pratap Sagar Tiwari has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Management of Hepatotoxicity and Utilization of Antitubercular Drugs in Chronic Liver Disease: A Narrative Review

    by Pratap Sagar Tiwari, Pukar Thapa

    The World Health Organization’s “End TB strategy” envisions a world free of tuberculosis (TB), emphasizing early diagnosis, effective treatment, and prevention. The Government of Nepal has incorporated innovative activities into its National Strategic Plan and the “TB Free Initiative.” Despite these initiatives, significant challenges remain, particularly concerning hepatotoxicity during antitubercular therapy, its management, and the treatment of tuberculosis in patients with chronic liver disease (CLD). Drug-induced liver injury (DILI) is a leading cause of treatment interruption, nonadherence, and therapeutic failure. Among these, antitubercular drug-induced liver injury (ATT-DILI) represents a distinct and clinically significant concern that requires focused attention. In patients with chronic liver disease, appropriate selection of antitubercular regimens based on the severity of liver disease is essential for successful TB treatment. A tailored approach that balances efficacy and safety is necessary. This article proposes a strategy based on monitoring and modification to assist clinicians in managing hepatotoxicity associated with antitubercular agents in patients with chronic liver disease.


  • Open Access

    Metabolic Dysfunction Associated Steatotic Liver Disease, Not Just Fatty Liver Disease: A Systemic Shift in Naming and Understanding

    by Pratap Sagar Tiwari

    The reclassification of fatty liver disease to Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) marks a paradigm shift. Moving beyond stigmatizing, misleading terms, MASLD emphasizes metabolic dysfunction as the root cause. This systemic condition links to cardiovascular, renal, and diabetic risks, demanding comprehensive screening, research, and public health action worldwide.

  • Open Access

    Clinical Profile of Patients with Chronic Liver Disease

    by Pratap Sagar Tiwari, Surendra Shah, Sudhamshu Kc

    Background: Chronic liver disease is a major problem worldwide. Understanding the demographics, clinical profile, and staging of the condition helps in forming a better management plan for the disease and which reflects the outcomes as well. Materials and Methods: Three hundred and eighty patients with chronic liver disease were prospectively studied at the Department of Hepatology in Nobel Medical college, which is a tertiary care hospital of eastern Nepal, from September 2023 to March 2024. Clinical characteristics, endoscopy results and lab reports were studied. Statistical Package for the Social Sciences (SPSS) version was used for the analysis. Results: Mean age was 48.3±11.1 years with 73 % males. The maximum number of patients [112 (29.5%)] belonged to the age group 45-54 years old. The aetiology of Chronic liver disease was alcohol-related in 81 %. Chronic Hepatitis B virus and Hepatitis C virus-related liver disease was found in 11.6% & 2.6 % of patients. Eighty-six percent had esophageal varices. There were 11.8% patients with MELD score 15. Based on the Child-Pugh score, 15.5% of patients were in CPC-A, 38.4% were in CPC-B, and 46.1% were in CPC-C at presentation. Conclusion: Alcohol-related liver disease is the most common cause of Chronic liver disease in Nepal, followed by Chronic Hepatitis B and Hepatitis C virus-related liver disease. Most patients present in their advanced stages, as reflected by esophageal varices and high MELD & Child Pugh scores.

  • Open Access

    Correlation of Child-Pugh Classification with Esophageal Varices in Patients with Liver Cirrhosis

    by Pratap Sagar Tiwari, Pukar Thapa, Binod Karki, Sudhamshu Kc

    Introduction: The severity of the chronic liver disease can be assessed by several non-invasive methods one of them includes scoring system like Child-Pugh classification. Aims: The objective of this study was to assess the correlation of Child Pugh class with esophageal varices in patients with liver cirrhosis. Methods: This was a cross-sectional hospital-based study of 406 patients with liver cirrhosis. Demographic and relevant clinical data were collected using a standardized questionnaire. Abdominal ultrasound, liver function test, full blood count, viral markers were done for all patients. All patients underwent upper gastrointestinal endoscopy to screen for varices and if found were categorized as small and large. Results: A total of 406 patients with a mean age of 48 ± 11 years were evaluated. There were 72.4% and 27.6% men and women respectively. Variceal screening by upper gastrointestinal endoscopy revealed esophageal varices in 90.1% patients. By Child-Pugh Classification, 60 (14.8%) patients were in class A, 156 (38.4%) in class B and 190 (46.8%) in class C. Among patients with Child class A, 29 (48.3%) had varices. Similarly, 147 (94.2%) and 190 (100%) of Child class B & C had varices respectively. Odds of presence of esophageal varix were 9 times higher for patients with Child-Pugh Classification B and C compared to class A. Conclusion: Most patients with cirrhosis present late and with advanced stage in this referral center. Most have esophageal varices on their first screening endoscopy. Child-Pugh classification is a reliable measure of stratifying variceal risk in chronic liver disease patients.


  • Open Access

    Spleen Stiffness Measurement as Non-Invasive Surrogate for Esophageal Varices in Chronic Liver Disease

    by Pratap Sagar Tiwari, Sudhamshu Kc

    Background: In patients with chronic liver diseases, liver and spleen stiffness measurement by elastography is the most recent available noninvasive tool. However, the accuracy for prediction of esophageal varices has been inconsistent across various studies. So, this study was done to evaluate the diagnostic performance of spleen stiffness measurement for detecting esophageal varices. Materials and Methods: This descriptive cross-sectional study was done from 19 March to 30 June 2019. Participants who met inclusion and exclusion criteria were consecutively enrolled for the study and underwent upper gastrointestinal endoscopic examination along with measurement of liver and spleen stiffness by fibroscan. Results: A total of 78 patients were enrolled. Mean age (±SD) was 49.79 (±10.92) years. Of 78 patients, 58 (74.4 %) had esophageal varices. Among patients with varices, Small esophageal varices were present in 44.8 % (26) and large esophageal varices were present in 55.2 % (32).Liver stiffness higher than 21.7 kPa was found to detect patients with large esophageal varices and the area under the receiver operating curve being 0.79 (95% confidence interval: 0.69 – 0.89); pConclusion: Spleen stiffness measurements by Transient Elastography predict large esophageal varices better than liver stiffness measurements.

  • Open Access

    Direct-Acting Antivirals in the Treatment of Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Co-infected Patients: Real-Life Experience From Nepal

    by Sudhamshu Kc, Niyanta Karki, Dilip Sharma, Sandip Khadka, Pratap S. Tiwari

    Direct-acting antivirals (DAA) have revolutionized the treatment of chronic hepatitis C patients. However, the real-life data regarding its use in a human immunodeficiency virus (HIV) co-infection from a developing country is lacking. We aimed to see the efficacy of DAA in hepatitis C virus (HCV)/HIV co-infected populations. In this prospective, observational, intention-to-treat study from Nepal, treatment-naïve patients undergoing treatment for chronic HCV in HIV co-infected individuals with DAA were studied. Patients on nevirapine were switched to efavirenz or atazanavir. Patients received sofosbuvir/ledipasvir or sofosbuvir/daclatasvir with or without ribavirine. Sustained virological response (SVR) at week 12, adverse events, and treatment compliance were evaluated. Treatment efficacy was compared between cirrhotic and non-cirrhotic patients. Of 218 patients presenting with an anti-HCV report, 181 (83%) had detectable HCV RNA. Eighty-five (85; 47%) patients were having ART at presentation. Three patients could not complete treatment due to gall stone pancreatitis and 82 completed treatment. Twenty-nine (29; 35%) were cirrhotic at presentation. Fifty-one (51; 62%) patients were genotype 3, 27 (33%) were genotype 1, three (4%) were mixed 1a/3, and one (1%) was 6. Seventy-four (74; 90%) had SVR12. Non-cirrhotics had 96% SVR compared to 79% in cirrhotics. SVR in genotype 3 was 88% while it was 93% in genotype 1. Real-life experience showed that the DAAs are equally effective in HCV HIV co-infected patients. In non-cirrhotic patients, the result is comparable to mono-infected patients. Genotype 3 co-infected are also difficult-to-treat patients. DAA treatment is well-tolerated in HCV/HIV co-infected patients, and there was no dropout during treatment.


  • Open Access

    Occult Hepatitis B Infection in End-Stage Renal Disease Patients Starting Maintenance Hemodialysis at a Tertiary Care Hospital: A Descriptive Cross-sectional Study

    by Shailendra Shrestha, Pratap Sagar Tiwari, Bikram Pradhan

    Introduction: Occult hepatitis B infection is defined as the presence of the hepatitis B virus deoxyribonucleic acid in liver tissues and/or serum in the absence of serum hepatitis B Virus surface antigen. The prevalence of occult hepatitis B infection in end-stage renal disease patients is largely unknown. The aim of the study is to determine the prevalence of occult hepatitis B infection in the hemodialysis population starting maintenance hemodialysis. Methods: A descriptive cross-sectional study was conducted in the department of Internal Medicine of a tertiary care hospital. Convenience sampling method was used; 50 consecutive end-stage renal disease patients, who started maintenance hemodialysis from March 2019 to March 2020, were enrolled in the study. The study was approved by the Institutional Review Committee of the hospital (reference number: 351/2019). Statistical Package for Social Sciences version 26.0 was used for statistical analysis. Results: The mean age of the patients was 50.34±12.65 years, and 42 (84%) were male. About 4 (8%) patients were diagnosed having occult hepatitis B infection, 3 (6%) of them were seropositive and 1 (2%) seronegative. About 41 (82%) patients had no history of hepatitis B vaccination series before starting hemodialysis; 36 (72%) had anti-hepatitis B surface antibody titre <10 mIU/ml. About 44 (88%) patients received a blood transfusion during their hemodialysis sessions and 14 (28%) patients had a history of receiving hemodialysis at other centres. Conclusions: Our study demonstrated a high prevalence of occult hepatitis B infection among end-stage renal disease patients starting hemodialysis.


  • Open Access

    Prevalence of Acute Kidney Injury in Patients with Liver Cirrhosis

    by Pukar Thapa, Sudhamshu Kc, Achyut Bikram Hamal, Dilip Sharma, Sandip Khadka, Niyanta Karki, Bikash Jaishi, Pratap Sagar Tiwari, Anshu Vaidya, Binod Karki

    Introduction: Acute kidney injury is a common and life-threatening event in patients with liver cirrhosis occurring in approximately 20-50% of hospitalized patients of liver cirrhosis. Pre-renal acute kidney injury, the hepatorenal syndrome type of acute kidney injury and acute tubular necrosis represent the common causes. The aim of this study was to study the profile of acute kidney injury in patients with liver cirrhosis. Methods: Consecutive patients of liver cirrhosis admitted in Liver unit of Bir Hospital were studied to see the presence of acute kidney injury in this hospital based descriptive cross-sectional study. Clinical and laboratory parameters along with various clinical outcome were compared between different groups categorized by the severity of liver disease and renal dysfunction. Results: Out of 302 liver cirrhosis patients, 56 (18.5%) had acute kidney injury among which 23 (46%) were found to have pre-renal acute kidney injury, 15 (30%) with hepatorenal syndrome– acute kidney injury and 12 (24%) with intrinsic renal disease. Patients with higher stages of acute kidney injury had longer duration of hospital stay and hepatorenal syndrome-acute kidney injury was seen in patients with higher grade of ascites and with hyponatremia. Conclusions: Acute kidney injury is a common occurrence in patients with advanced liver cirrhosis with pre-renal acute kidney injury being the commonest cause. Median hospital stay is directly affected by the severity of acute kidney injury and hepatorenal syndrome–acute kidney injury was seen in patients with higher grade of ascites and hyponatremia. Early identification of patients at high risk for acute kidney injury may help to reduce mortality and contain costs.


  • Von-Willebrand factor: A biomarker to predict in-hospital survival in patients with severe and very severe alcoholic hepatitis

    by Ce Eapen, Pratap Sagar Tiwari, Ks Prasanna, Pb Gandhi, Sc Nair, Gj Amirtharaj, Ka Balasubramanian, Anup Ramachandran, Ian Mackie, U Zachariah, et al.

    Objectives: The aim of this study is to assess the utility of plasma von-Willebrand factor (VWF) levels in predicting in-hospital survival for patients with severe alcoholic hepatitis. Methods: From a prospectively collected database of acute-on-chronic liver failure (ACLF) patients, we retrospectively selected all severe alcoholic hepatitis (discriminant function [DF] ≥32) patients and correlated baseline plasma VWF (antigen, Ag and collagen-binding activity [CBA]) levels with disease severity. In-hospital survival was classified as discharged alive (or) died/discharged in a terminal condition (poor outcome). Results: Of 34 consecutive severe alcoholic hepatitis patients (age: 40.5, 30–63 years; median, range, hospital stay: 6, 2–15 days) studied, 15 had a poor outcome. Plasma VWF-CBA was higher in patients with poor outcome (736 [396–1157] IU/dL) as compared to patients discharged in stable state (492 [97–986] IU/dL; P = 0.03). VWF-CBA correlated well with VWF-Ag, model for end-stage liver disease (MELD) score, sequential organ failure assessment score and ACLF grades. AUROC to predict composite poor outcome was similar for plasma VWF-CBA (0.72, 0.54–0.89) and MELD score (0.71, 0.53–0.89). Plasma VWF-CBA was higher in 23 “very severe” alcoholic hepatitis (DF >60 or MELD >30) patients. Combining plasma VWF-CBA (>750 IU/dL) and criteria for “very severe” alcoholic hepatitis had a sensitivity of 100% (81%–100%) and negative predictive value of 100% (68%–100%) for predicting poor outcome. Conclusions: Plasma VWF levels are markedly elevated, correlate with organ failure, and predict in-hospital survival in severe alcoholic hepatitis, and also in “very severe” alcoholic hepatitis, patients.


  • Open Access

    Prevalence of Portal Hypertensive Gastropathy in Chronic Liver Disease and Correlation with the Severity of Liver disease

    by Pratap S. Tiwari, Sudhamshu Kc, Dilip Sharma, Mukesh S. Paudel, Amrendra Mandal

    Portal hypertensive gastropathy (PHG) is an underappreciated condition in patients with chronic liver disease (CLD). It is a common endoscopic finding in CLD patients, but its relation with esophageal varices (EV) and the severity of the liver disease is controversial. Herein, we aimed to study the prevalence of PHG in CLD patients and to determine its association with EV and the severity of the liver disease. This descriptive, cross-sectional, analytical study was conducted at the Hepatology department, Bir Hospital Kathmandu from 19th March to 30th June 2019. A total of 404 patients with CLD of various etiology fulfilling the inclusion criteria were approached, and informed consent was taken before enrolling in the study. All patients underwent EGD, and the findings related to EV and PHG were noted. The severity of PHG was graded according to the McCormack classification and EV were graded according to the American Association for the study of liver diseases guideline. The severity of liver disease was stratified based on Child-Pugh class and Model for End-Stage Liver Disease (MELD score). Data was entered on Statistical Package for the Social Sciences (SPSS) Version 25 for further analysis. Of 404 CLD patients, the mean (±SD) age was 49.14 (±10.5) years. Portal hypertensive gastropathy was observed in 269 (66.6%) patients, of which 80.6% (217) had mild PHG while 19.4% (52) had severe PHG. EV were present in 362 (89.6%) patients. One hundred and thirty-two (36.5%) had small EV, and 230 (63.5%) had large EV. No significant association was observed between grades of gastropathy and size of varices (p = 0.36). There was a non-significant association with the MELD score and other biochemical parameters. However, there were significant associations between Child-Pugh class and PHG and Child-Pugh class and PHG severity, p = 0.001 and p = 0.01 (p <0.05), respectively. In our study, the prevalence of PHG in the Nepalese population in CLD is 66.6 %. PHG is significantly associated with the severity of CLD in terms of Child-Pugh class but not associated with MELD. Also, no association has been found with the size of varices.